Y-mAbs Therapeutics
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
202 Carnegie Ctr Ste 301, Princeton, New...Phone Number
(646) 885-8505Website
www.ymabs.comRevenue
$85.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Y-mAbs Therapeutics
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.Explore more
Y-mAbs Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Y-mAbs Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Y-mAbs Therapeutics launches new products
Click to see if Y-mAbs Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Y-mAbs Therapeutics
Check out if Y-mAbs Therapeutics is spiking on competitors!
Earning: See what the market has to say on Y-mAbs Therapeutics recently announced quarterly report
Y-mAbs Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Y-mAbs Therapeutics has new funding data
Check if Y-mAbs Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Y-mAbs Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Y-mAbs Therapeutics
Compare insights from companies similar to Y-mAbs Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Y-mAbs Therapeutics
$85.4M
51-200
Private
$434.2M
2015
RG
Robert GunningVice President, Finance & Corporate Controller
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Y-mAbs Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Y-mAbs Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Y-mAbs Therapeutics.
Y-mAbs Therapeutics financials insights
Gather financial insights about Y-mAbs Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Share Placement
$80M
2018
Stock Offering
$110.4M
2019
Stock Offering
$143.8M
2021
Stock Offering
$100M
Y-mAbs Therapeutics Tech Stack
A closer look at the technologies used by Y-mAbs Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Y-mAbs Therapeutics News & Media
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is one of the 11 Best Short-Term Stocks to Invest in. A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks’ performance. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company’s lead product, DANYELZA® […]Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025.Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Click here to learn how to join our investigation and obtain additional...SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Y-mAbs Therapeutics
Sign Up For FreeTo access detailed company insights
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivot... Read More
